Similar companies
Income Statement ()
Q2 '24 | QoQ |
---|
Balance Sheet ()
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 15M | 15% |
Total Liabilities | 22M | 0.4% |
Shares Outstanding | 3.35B | 80.4% |
Cash Flow ()
Q2 '24 | QoQ |
---|
EPS
Financial Highlights for Scinai Immunotherapeutics in Q2 '24
Scinai Immunotherapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.